Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Multiple Cancer Types

Dermatologic, Melanoma
N/A
Kauffmann, Rondi
VICCMEL0287

Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

Melanoma

Melanoma
N/A
Johnson, Douglas
NCT01205815
VICCMEL09109

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Melanoma

Melanoma
N/A
Johnson, Douglas
NCT02173171
VICCMEL14103

Investigating Immune Responses in Patients with Advanced Melanoma Treated with Immune-Based Therapy

Melanoma

Melanoma
N/A
Irish, Jonathan
VICCMEL15148

Wren Melanoma Study

Melanoma

Melanoma
N/A
Kauffmann, Rondi
NCT03267381
VICCMEL1783

Nivolumab and Relatlimab or Ipilimumab in Treating Patients with Locally Advanced, Unresectable, or Metastatic Melanoma

Melanoma

This phase II trial studies how well nivolumab given together with relatlimab or ipilimumab works in treating patients with melanoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, relatlimab, and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Melanoma
II
Davis, Elizabeth
NCT03724968
VICCMEL18114

Testing Treatment with Ipilimumab and Nivolumab Compared to Treatment with Ipilimumab Alone in Advanced Melanoma

Melanoma

This phase II trial studies how well ipilimumab with or without nivolumab work in treating patients with melanoma that is stage IV or stage III and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Melanoma
II
Johnson, Douglas
NCT03033576
ECOGMELS1616

A Study to Compare the Administration of Pembrolizumab after Surgery Versus Administration both before and after Surgery for High-Risk Melanoma

Melanoma

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.
Melanoma
II
Davis, Elizabeth
NCT03698019
ECOGMELS1801

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: